Dichotomy_NN of_IN Glycoprotein_NP G_NP Gene_NP in_IN Herpes_NP Simplex_NP Virus_NP Type_NP 1_CD Isolates_NP Herpes_NP simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) encodes_VBZ 11_CD envelope_NN glycoproteins_NNS ,_, of_IN which_WDT glycoprotein_NN G-1_NP (_( gG-1_NN )_) induces_VBZ a_DT type-specific_JJ antibody_NN response_NN ._SENT Variability_NN of_IN the_DT gG-1_JJ gene_NN among_IN wild-type_NN strains_NNS may_MD be_VB a_DT factor_NN of_IN importance_NN for_IN a_DT reliable_JJ serodiagnosis_NN and_CC typing_VBG of_IN HSV-1_JJ isolates_NNS ._SENT Here_RB ,_, we_PP used_VBD a_DT gG-1_JJ type-specific_JJ monoclonal_NN antibody_NN (_( MAb_NP )_) to_TO screen_VB for_IN mutations_NNS in_IN the_DT immunodominant_JJ region_NN of_IN this_DT protein_NN in_IN 108_CD clinical_JJ HSV-1_JJ isolates_NNS ._SENT Of_IN these_DT ,_, 42_CD isolates_NNS showed_VBD no_DT reactivity_NN to_TO the_DT anti-gG-1_JJ MAb_NP ._SENT One_CD hundred_CD five_CD strains_NNS were_VBD further_RBR examined_VBN by_IN DNA_NP sequencing_NP of_IN the_DT middle_JJ part_NN of_IN the_DT gG-1_JJ gene_NN ,_, encompassing_VBG 106_CD amino_NN acids_NNS including_VBG the_DT immunodominant_JJ region_NN and_CC epitope_NN of_IN the_DT anti-gG-1_JJ MAb_NP ._SENT By_IN phylogenetic_JJ comparisons_NNS based_VBN on_IN the_DT sequence_NN data_NNS ,_, we_PP observed_VBD two_CD (_( main_JJ )_) genetic_JJ variants_NNS of_IN the_DT gG-1_JJ gene_NN among_IN the_DT clinical_JJ isolates_NNS corresponding_JJ to_TO reactivity_NN or_CC nonreactivity_NN to_TO the_DT anti-gG-1_JJ MAb_NP ._SENT Furthermore_RB ,_, four_CD strains_NNS appeared_VBD to_TO be_VB recombinants_NNS of_IN the_DT two_CD gG-1_JJ variants_NNS ._SENT In_IN addition_NN ,_, one_CD strain_NN displayed_VBD a_DT gG-1-negative_JJ phenotype_NN due_JJ to_TO a_DT frameshift_NN mutation_NN ,_, in_IN the_DT form_NN of_IN insertion_NN of_IN a_DT cytosine_NN nucleotide_NN ._SENT When_WRB immunoglobulin_NN G_NN reactivity_NN to_TO HSV-1_NP in_IN sera_NN from_IN patients_NNS infected_VBN with_IN either_CC of_IN the_DT two_CD variants_NNS was_VBD investigated_VBN ,_, no_DT significant_JJ differences_NNS were_VBD found_VBN between_IN the_DT two_CD groups_NNS ,_, either_CC in_IN a_DT type-common_NN enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) or_CC in_IN a_DT type-specific_JJ gG-1_JJ antigen-based_JJ ELISA_NP ._SENT Despite_IN the_DT here-documented_JJ existence_NN of_IN two_CD variants_NNS of_IN the_DT gG-1_JJ gene_NN affecting_VBG the_DT immunodominant_JJ region_NN of_IN the_DT protein_NN ,_, other_JJ circumstances_NNS ,_, such_JJ as_IN early_JJ phase_NN of_IN infection_NN ,_, might_MD be_VB sought_VBN for_IN explaining_VBG the_DT seronegativity_NN to_TO gG-1_NN commonly_RB found_VBD in_IN a_DT proportion_NN of_IN the_DT HSV-1-infected_JJ patients_NNS ._SENT Herpes_NN simplex_NN virus_NN (_( HSV_NP )_) is_VBZ an_DT alpha-herpesvirus_NN with_IN two_CD subtypes_NNS ,_, HSV_NP type_NN 1_CD (_( HSV-1_NP )_) and_CC HSV-2_NP ,_, which_WDT both_CC establish_VB latent_JJ infections_NNS with_IN different_JJ or_CC similar_JJ clinical_JJ expressions_NNS during_IN reactivation_NN ._SENT The_DT ability_NN to_TO discriminate_VB between_IN HSV-1_NP and_CC HSV-2_NP infections_NNS by_IN serological_JJ means_NNS has_VBZ been_VBN of_IN importance_NN for_IN several_JJ clinical_JJ aspects_NNS ,_, including_VBG diagnosis_NN and_CC treatment_NN of_IN neonatal_JJ herpes_NN as_IN well_RB as_RB of_IN complications_NNS from_IN the_DT central_JJ nervous_JJ system_NN ._SENT Glycoprotein_NN G-1_NP (_( gG-1_JJ )_) ,_, a_DT viral_JJ envelope_NN glycoprotein_NN that_WDT was_VBD suggested_VBN to_TO contribute_VB to_TO viral_JJ entry_NN through_IN apical_JJ surfaces_NNS of_IN polarized_VBN cells_NNS ,_, has_VBZ been_VBN utilized_VBN as_IN a_DT prototype_NN antigen_NN for_IN HSV-1_JJ type-specific_JJ diagnosis_NN due_JJ to_TO lack_NN of_IN cross-reactivity_NN with_IN its_PP$ counterpart_NN in_IN HSV-2_NP ,_, i.e._FW ,_, gG-2_JJ ._SENT Several_JJ commercial_JJ gG-based_JJ enzyme_NN immunoassays_NNS have_VBP been_VBN evaluated_VBN in_IN clinical_JJ settings_NNS ._SENT Furthermore_RB ,_, gG-1_NN may_MD be_VB a_DT suitable_JJ target_NN for_IN typing_VBG of_IN HSV_NP isolates_VBZ by_IN monoclonal_NN antibodies_NNS (_( MAb_NP )_) that_WDT identify_VBP type-specific_JJ epitopes_NNS ._SENT Conservation_NN of_IN the_DT gene_NN coding_VBG for_IN gG-1_NN among_IN clinical_JJ HSV-1_JJ isolates_NNS might_MD therefore_RB be_VB a_DT prerequisite_NN for_IN a_DT reliable_JJ assessment_NN of_IN a_DT type-specific_JJ antibody_NN response_NN as_IN well_RB as_RB of_IN correct_VB typing_VBG of_IN isolates_NNS in_IN individuals_NNS infected_VBN with_IN HSV-1_NP ._SENT In_IN a_DT previous_JJ study_NN ,_, several_JJ point_NN mutations_NNS were_VBD found_VBN when_WRB the_DT gG-1_JJ genes_NNS of_IN 11_CD HSV-1_JJ clinical_JJ strains_NNS and_CC two_CD reference_NN strains_NNS were_VBD sequenced_JJ ,_, and_CC some_DT of_IN these_DT mutations_NNS were_VBD present_JJ within_IN a_DT recently_RB defined_VBN immunodominant_JJ region_NN including_VBG the_DT epitope_NN of_IN a_DT type-specific_JJ anti-gG-1_JJ MAb_NN ._SENT Genetic_JJ variability_NN of_IN this_DT gene_NN among_IN clinical_JJ isolates_NNS may_MD therefore_RB be_VB of_IN importance_NN for_IN the_DT immunoglobulin_NN G_NP (_( IgG_NP )_) response_NN within_IN the_DT individual_JJ host_NN when_WRB a_DT predefined_JJ gG-1_JJ antigen_NN is_VBZ used_VBN for_IN detection_NN ._SENT Previously_RB ,_, a_DT few_JJ studies_NNS have_VBP described_VBN a_DT limited_JJ genetic_JJ variability_NN of_IN genes_NNS coding_VBG for_IN envelope_NN glycoprotein_NN among_IN HSV-1_JJ strains_NNS as_IN shown_VBN by_IN DNA_NP sequencing_NP of_IN the_DT gB-gene_NN or_CC the_DT gD_JJ gene_NN after_IN PCR_NP amplification_NN of_IN cerebrospinal_JJ fluid_JJ samples_NNS ._SENT These_DT studies_NNS observed_VBD some_DT point_NN mutations_NNS which_WDT were_VBD mostly_RB silent_JJ ,_, and_CC the_DT insertion_NN or_CC deletion_NN of_IN one_CD or_CC a_DT few_JJ codons_NNS compared_VBN to_TO a_DT previously_RB published_VBN HSV-1_JJ sequence_NN ._SENT In_IN contrast_NN to_TO this_DT ,_, we_PP here_RB report_VB the_DT identification_NN of_IN two_CD major_JJ genetic_JJ variants_NNS of_IN the_DT gG-1_JJ gene_NN based_VBN on_IN DNA_NP sequencing_NP and_CC investigation_NN of_IN MAb_NP reactivity_NN to_TO a_DT type-specific_JJ gG-1_JJ epitope_NN in_IN a_DT large_JJ number_NN of_IN clinical_JJ isolates_NNS ._SENT Altogether_RB ,_, 42_CD strains_NNS were_VBD found_VBN to_TO be_VB unreactive_JJ to_TO the_DT anti-gG-1_JJ MAb_NN among_IN the_DT 108_CD HSV-1_JJ clinical_JJ isolates_NNS ,_, a_DT finding_NN that_WDT was_VBD explained_VBN by_IN the_DT existence_NN of_IN two_CD genetic_JJ variants_NNS discovered_VBD when_WRB the_DT strains_NNS were_VBD subjected_VBN to_TO DNA_NP sequencing_NP of_IN the_DT middle_JJ part_NN of_IN the_DT gG-1_JJ gene_NN ._SENT However_RB ,_, no_DT differences_NNS in_IN IgG_NP reactivity_NN were_VBD found_VBN when_WRB sera_NN from_IN patients_NNS harboring_VBG either_RB of_IN these_DT variants_NNS were_VBD compared_VBN by_IN gG-1_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) ._SENT Patients_NNS and_CC viral_JJ strains_NNS ._SENT |_SYM The_DT study_NN material_NN is_VBZ schematically_RB presented_VBN in_IN Fig._NN ._SENT One_CD hundred_CD six_CD patients_NNS with_IN reactivated_VBN herpetic_JJ lesions_NNS from_IN different_JJ anatomical_JJ sites_NNS (_( oral_JJ ,_, facial_JJ ,_, genital_JJ ,_, perianal_JJ ,_, and_CC others_NNS ;_: see_VB Table_NP )_) were_VBD randomly_RB chosen_VBN for_IN investigation_NN ,_, and_CC 108_CD virus_NN strains_NNS derived_VBN from_IN these_DT 106_CD patients_NNS were_VBD consecutively_RB received_VBN at_IN the_DT Department_NP of_IN Clinical_NP Virology_NP ,_, Goteborg_NP ._SENT Green_JJ monkey_NN kidney_NN (_( GMK_NP )_) cells_NNS were_VBD used_VBN for_IN isolation_NN of_IN the_DT virus_NN strains_NNS ,_, which_WDT all_RB were_VBD typed_VBN as_IN HSV-1_NP by_IN the_DT use_NN of_IN a_DT type-specific_JJ anti-gC_NP MAb_NP ._SENT Of_IN the_DT 106_CD patients_NNS ,_, documentation_NN of_IN gender_NN was_VBD available_JJ for_IN 76_CD subjects_NNS ,_, of_IN whom_WP 54_CD were_VBD women_NNS and_CC 22_CD were_VBD men_NNS ._SENT From_IN 53_CD patients_NNS ,_, a_DT serum_NN sample_NN was_VBD drawn_VBN and_CC included_VBN for_IN serological_JJ assays_NNS ._SENT From_IN two_CD of_IN these_DT patients_NNS ,_, two_CD isolates_NNS were_VBD investigated_VBN :_: one_CD strain_NN from_IN the_DT thoracic_JJ region_NN and_CC one_CD from_IN penis_NN in_IN one_CD patient_NN ,_, and_CC one_CD isolate_NN from_IN the_DT lip_NN and_CC one_CD from_IN the_DT genital_JJ region_NN in_IN another_DT patient_NN ._SENT The_DT study_NN was_VBD approved_VBN by_IN the_DT Medical_NP Ethical_JJ Committee_NP in_IN Goteborg_NP ,_, Sweden_NP ,_, (_( approval_NN no_RB ._SENT :_: S_NP 266-00_CD )_) ._SENT MAbs_NP ._SENT |_SYM The_DT following_VBG HSV-1_JJ type-specific_JJ MAbs_NNS were_VBD used_VBN :_: a_DT commercially_RB available_JJ anti-gG-1_JJ MAb_NP (_( Advanced_NP Biotechnologies_NP Incorporated_VBD )_) ,_, which_WDT was_VBD previously_RB mapped_VBN by_IN a_DT pepscan_JJ technique_NN to_TO the_DT amino_NN acids_NNS AFPL_NN at_IN position_NN 110_CD to_TO 113_CD ,_, the_DT anti-gC-1_JJ MAb_NP B1C1B4_NP ,_, and_CC the_DT anti-gB-1_JJ MAb_NP 1B11D8_NP ._SENT For_IN typing_VBG of_IN HSV-2_JJ strains_NNS ,_, the_DT anti-gG-2_JJ MAb_NP O1C5B2_NP was_VBD used_VBN ._SENT Type-specific_JJ serology_NN ._SENT |_SYM An_NP ELISA_NP was_VBD used_VBN to_TO determine_VB type-common_NN and_CC HSV-1_JJ and_CC HSV-2_JJ type-specific_JJ antibody_NN reactivity_NN in_IN serum_NN samples_NNS ._SENT In_IN brief_NN ,_, the_DT type-common_NN antigen_NN was_VBD based_VBN on_IN sodium_NN deoxycholate-solubilized_VBD membranes_NNS from_IN cells_NNS infected_VBN with_IN HSV-1_JJ strain_NN F_NN ._SENT The_DT HSV-1_JJ type-specific_JJ antigen_NN was_VBD based_VBN on_IN the_DT gG-1_JJ protein_NN (_( kindly_RB provided_VBN by_IN SmithKline_NP Beecham_NP Biologicals_NP )_) ,_, and_CC seroreactivity_NN was_VBD analyzed_VBN by_IN ELISA_NP as_IN previously_RB described_VBN ._SENT The_DT HSV-2_NP type-specific_JJ assay_NN was_VBD based_VBN on_IN Helix_NP pomatia_NP lectin-purified_JJ gG-2_NN ._SENT For_IN the_DT type-common_NP and_CC HSV-2_NP ELISA_NP assays_NNS ,_, serum_NN samples_NNS were_VBD diluted_VBN to_TO 1/100_CD ,_, and_CC for_IN the_DT HSV-1_NP ELISA_NP ,_, serum_NN samples_NNS were_VBD diluted_VBN to_TO 1/50_CD for_IN further_JJR titration_NN ._SENT Alkaline_JJ phosphatase-conjugated_JJ ,_, affinity-purified_JJ F(ab)2_NP fragment_NN goat_NN anti-human_NP IgG_NP (_( Jackson_NP ImmunoResearch_NP Lab_NP )_) was_VBD used_VBN at_IN a_DT 1/3,500_CD dilution_NN ._SENT p-Nitrophenyl_NN phosphate_NN was_VBD used_VBN as_IN a_DT substrate_NN at_IN a_DT concentration_NN of_IN 1_CD mg/ml_NN ._SENT The_DT A405_NP value_NN was_VBD measured_VBN with_IN a_DT reference_NN wavelength_NN of_IN 650_CD nm_NN against_IN a_DT substrate_NN blank_NN ._SENT The_DT cutoff_NN value_NN was_VBD calculated_VBN using_VBG the_DT optical_JJ density_NN (_( OD_JJ )_) value_NN of_IN the_DT negative_JJ controls_NNS (_( previously_RB found_VBN to_TO be_VB HSV-negative_JJ by_IN HSV-1_NP and_CC HSV-2_NP Western_NP blot_NN )_) plus_CC 0.2_CD OD_NP U_NP for_IN the_DT type-common_NN ,_, as_RB well_RB as_IN for_IN the_DT gG-1_NN ,_, ELISA_NP ._SENT In_IN the_DT gG-2_JJ ELISA_NP the_DT OD_JJ value_NN of_IN high-titrating_VBG HSV-1-positive_JJ sera_NN plus_CC 0.1_CD OD_NNS U_NP was_VBD used_VBN as_IN a_DT cutoff_NN value_NN ._SENT When_WRB comparing_VBG the_DT two_CD groups_NNS ,_, the_DT netto-absorbance_NN (_( absorbance_NN minus_CC background_NN ,_, which_WDT was_VBD bovine_JJ serum_NN albumin_NN )_) value_NN was_VBD used_VBN ,_, in_IN order_NN to_TO give_VB consideration_NN to_TO differences_NNS that_WDT might_MD occur_VB when_WRB developing_VBG the_DT plates_NNS ._SENT Indirect_JJ immunofluorescence_NN ._SENT |_SYM To_TO investigate_VB whether_IN subjects_NNS with_IN HSV-1_NP IgG-negative_NP sera_NN experienced_VBD a_DT primary_JJ infection_NN ,_, IgM_NP antibodies_NNS were_VBD analyzed_VBN by_IN an_DT in-house_JJ immunofluorescence_NN assay_NN using_VBG HSV-2-infected_NP GMK_NP cells_NNS as_IN antigen_NN ._SENT The_DT assay_NN was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT ELISA_NN with_IN infected_JJ cells_NNS ._SENT |_SYM For_IN screening_NN of_IN mutations_NNS within_IN type-specific_JJ epitopes_NNS of_IN gG-1_NN by_IN the_DT use_NN of_IN a_DT MAb_NP ,_, an_DT ELISA_NP was_VBD performed_VBN with_IN cells_NNS infected_VBN with_IN the_DT different_JJ virus_NN strains_NNS ._SENT GMK_NN cells_NNS were_VBD grown_VBN on_IN 96-well_NN plates_NNS in_IN Eagle_NP 's_POS minimal_JJ essential_JJ medium_NN supplemented_VBN with_IN 1_CD %_NN PEST_NN ._SENT The_DT cells_NNS were_VBD infected_VBN with_IN the_DT HSV-1_JJ strains_NNS at_IN an_DT infectious_JJ dose_NN of_IN 106_CD PFU/ml_NN ._SENT The_DT anti-gG-1_NP MAb_NP was_VBD used_VBN at_IN a_DT dilution_NN of_IN 1:500_CD ,_, and_CC the_DT MAbs_NP B1C1B4_NP (_( reactive_JJ with_IN gC-1_NN )_) and_CC O1C5B2_NP (_( reactive_JJ with_IN gG-2_NN )_) were_VBD used_VBN at_IN a_DT dilution_NN of_IN 1:50_CD ._SENT As_IN conjugate_JJ for_IN the_DT MAbs_NP ,_, alkaline_JJ phosphate-_NN conjugated_VBN F(ab)2_NP goat_NN anti-mouse_NP IgG_NP was_VBD used_VBN at_IN a_DT dilution_NN of_IN 1:2,000_CD (_( Jackson_NP ImmunoResearch_NP Lab_NP )_) ._SENT As_IN the_DT substrate_NN ,_, p-nitrophenylphosphate_NN was_VBD used_VBN at_IN a_DT concentration_NN of_IN 1_CD mg/ml_NN ._SENT The_DT A405_NP value_NN was_VBD measured_VBN with_IN a_DT reference_NN wavelength_NN of_IN 650_CD nm_NN against_IN a_DT substrate_NN blank_NN ._SENT DNA_NP sequencing_NP of_IN the_DT gG-1_JJ gene_NN ._SENT |_SYM Viral_NP DNA_NP was_VBD prepared_VBN from_IN stock_NN viruses_NNS by_IN using_VBG the_DT QIAmp_JJ blood_NN kit_NN (_( Qiagen_NP )_) method_NN ,_, and_CC the_DT DNA_NN was_VBD subjected_VBN to_TO PCR_NP amplification_NN ._SENT Three_CD overlapping_JJ oligonucleotide_NN pairs_NNS were_VBD used_VBN as_IN primers_NNS for_IN complete_JJ gG-1_JJ gene_NN sequencing_VBG as_RB described_VBN previously_RB ._SENT Since_IN our_PP$ previous_JJ studies_NNS showed_VBD that_IN the_DT immunodominant_JJ region_NN ,_, as_RB well_RB as_IN most_JJS of_IN the_DT mutations_NNS ,_, was_VBD located_VBN within_IN the_DT region_NN amplified_VBN by_IN the_DT second_JJ primer_NN pair_NN ,_, this_DT part_NN was_VBD selected_VBN for_IN sequencing_VBG of_IN all_DT isolates_NNS with_IN the_DT exception_NN of_IN three_CD strains_NNS ._SENT In_IN addition_NN ,_, a_DT group_NN of_IN consecutively_RB received_VBN isolates_NNS was_VBD chosen_VBN for_IN sequencing_VBG of_IN the_DT complete_JJ gG-1_JJ gene_NN ,_, preferentially_RB those_DT for_IN which_WDT a_DT corresponding_JJ serum_NN sample_NN was_VBD collected_VBN ._SENT Amplified_VBN products_NNS were_VBD separated_VBN on_IN a_DT 1_CD %_NN agarose_NN gel_NN prior_RB to_TO extraction_NN of_IN the_DT amplicon_NN bands_NNS with_IN the_DT QIAquick_NP gel_NN extraction_NN kit_NN (_( Qiagen_NP )_) ._SENT PCR_NP cycle_NN sequencing_NP was_VBD carried_VBN out_RP by_IN using_VBG the_DT fluorescence-labeled_JJ stop_NN nucleotides_NNS with_IN dRhodamine_JJ terminator_NN cycle_NN sequencing_VBG ready_JJ reaction_NN kit_NN (_( Applied_NP Biosystems_NP )_) ._SENT The_DT sequencing_NP reaction_NN was_VBD carried_VBN out_RP in_IN both_DT sense_NN and_CC antisense_NN directions_NNS for_IN confirmation_NN and_CC also_RB to_TO act_VB as_IN an_DT internal_JJ control_NN ._SENT After_IN precipitation_NN with_IN ethanol_NN ,_, the_DT labeled_VBN samples_NNS were_VBD analyzed_VBN on_IN an_DT automated_JJ sequencer_NN (_( ABI_NP Prism_NP 310_CD genetic_JJ analyzer_NN ;_: Applied_NP Biosystems_NP )_) ._SENT In_IN addition_NN ,_, DNA_NN sequence_NN data_NNS from_IN the_DT gG-1_JJ gene_NN in_IN 10_CD HSV-1_JJ strains_NNS from_IN a_DT previous_JJ study_NN were_VBD included_VBN for_IN comparison_NN of_IN deduced_VBN amino_NN acid_NN sequences_NNS ._SENT Phylogenetic_JJ analysis_NN ._SENT |_SYM After_IN alignment_NN of_IN 105_CD sequences_NNS from_IN the_DT present_JJ study_NN and_CC 10_CD database_NN sequences_NNS (_( including_VBG KOS321_NP ,_, F_NP ,_, and_CC Syn17+_NP )_) ,_, phylogenetic_JJ comparison_NN was_VBD done_VBN ,_, after_IN bootstrapping_NN to_TO 500_CD replicates_VBZ ,_, by_IN distance_NN matrix/UPGMA_NN analysis_NN using_VBG the_DT MEGA2_JJ software_NN package_NN available_JJ at_IN ._SENT Trees_NNS were_VBD first_RB constructed_VBN by_IN comparison_NN of_IN an_DT entire_JJ sequence_NN (_( nucleotides_NNS [_SYM nt_RB ]_SYM 136950_CD to_TO 137238_CD in_IN Syn17+_NP according_VBG to_TO GenBank_NP )_) ._SENT For_IN evaluation_NN of_IN recombination_NN ,_, separate_JJ trees_NNS comparing_VBG two_CD parts_NNS ,_, nt_VBG 1_CD to_TO 100_CD and_CC nt_VBD 101_CD to_TO 288_CD ,_, was_VBD also_RB done_VBN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Statistical_NP analyses_NNS were_VBD performed_VBN by_IN Student_NP 's_POS t_NN test_NN ._SENT Nucleotide_NN sequence_NN accession_NN numbers_NNS ._SENT |_SYM The_DT nucleotide_NN sequences_NNS of_IN the_DT viruses_NNS were_VBD submitted_VBN to_TO GenBank_NP and_CC given_VBN the_DT accession_NN numbers_VBZ to_TO ._SENT FIG._NN 1_CD ._SENT |_SYM Schematic_NP presentation_NN of_IN the_DT virus_NN isolates_VBZ ,_, DNA_NP sequencing_NP of_IN the_DT gG-1_JJ gene_NN ,_, and_CC availability_NN of_IN corresponding_JJ serum_NN samples_NNS ._SENT Schematic_JJ presentation_NN of_IN the_DT virus_NN isolates_VBZ ,_, DNA_NP sequencing_NP of_IN the_DT gG-1_JJ gene_NN ,_, and_CC availability_NN of_IN corresponding_JJ serum_NN samples_NNS ._SENT *_SYM ,_, in_IN two_CD additional_JJ strains_NNS in_IN each_DT group_NN lacking_VBG corresponding_JJ sera_NN ,_, the_DT gG-1_JJ gene_NN was_VBD also_RB completely_RB sequenced_JJ ._SENT FIG._NN 2_CD ._SENT |_SYM (_( A_DT to_TO C_NP )_) Phylogenetic_JJ trees_NNS created_VBN by_IN distance_NN matrix/UPGMA_NN analysis_NN using_VBG MEGA_NP version_NN 2_CD ._SENT (_( A_DT to_TO C_NP )_) Phylogenetic_JJ trees_NNS created_VBN by_IN distance_NN matrix/UPGMA_NN analysis_NN using_VBG MEGA_NP version_NN 2.0_CD ._SENT Bootstrap_NN values_NNS above_IN 70_CD are_VBP displayed_VBN ._SENT The_DT phylogenetic_JJ trees_NNS included_VBD 30_CD unique_JJ sequences_NNS after_IN comparison_NN of_IN all_DT 115_CD gG-1_JJ sequences_NNS ._SENT The_DT AF120934_NP (_( strain_NN F_NN )_) sequence_NN was_VBD found_VBN in_IN 35_CD further_JJR samples_NNS ,_, NC_001806_NP (_( Syn17+_NP )_) was_VBD found_VBN in_IN 18_CD samples_NNS ,_, AF116193_NP was_VBD found_VBN in_IN 25_CD samples_NNS ,_, 66_CD was_VBD found_VBN in_IN 3_CD samples_NNS ,_, and_CC 49_CD ,_, 55_CD ,_, 64_CD ,_, and_CC 72_CD were_VBD found_VBN in_IN 1_CD additional_JJ sample_NN each_DT ._SENT The_DT trees_NNS in_IN panel_NN A_DT are_VBP based_VBN on_IN the_DT whole_JJ 288-nt_JJ sequence_NN ._SENT Panels_NNS B_NP and_CC C_NP were_VBD dated_VBN by_IN comparing_VBG the_DT segments_NNS 1_CD to_TO 100_CD and_CC 101_CD to_TO 288_CD separately_RB to_TO evaluate_VB suspected_JJ recombination_NN in_IN five_CD strains_NNS (_( 34_CD ,_, 66_CD ,_, 67_CD ,_, 70_CD ,_, and_CC AF117121_NP )_) ,_, denoted_VBN in_IN bold_JJ ._SENT TABLE_NN 1_CD |_SYM Sites_NP of_IN lesions_NNS and_CC anti-gG-1_JJ MAb_NP reactivities_NNS of_IN 108_CD clinical_JJ HSV-1_NP isolates_NNS Reactivity_NN of_IN an_DT anti-gG-1_JJ MAb_NN to_TO clinical_JJ HSV-1_JJ strains_NNS ._SENT |_SYM When_WRB the_DT 108_CD HSV-1_NP isolates_NNS were_VBD investigated_VBN for_IN reactivity_NN using_VBG an_DT anti-gG-1-specific_JJ MAb_NP by_IN ELISA_NP on_IN infected_JJ GMK_NP cells_NNS ,_, 42_CD clinical_JJ isolates_NNS showed_VBD no_DT reactivity_NN ,_, and_CC these_DT strains_NNS were_VBD derived_VBN from_IN different_JJ anatomical_JJ sites_NNS ._SENT In_IN contrast_NN ,_, all_DT isolates_NNS were_VBD reactive_JJ with_IN the_DT anti-gC-1_JJ MAb_NN ,_, and_CC none_NN were_VBD reactive_JJ with_IN the_DT anti-gG-2_JJ MAb_NP ._SENT As_IN a_DT likely_JJ explanation_NN ,_, all_RB of_IN the_DT 42_CD HSV-1_NP strains_NNS contained_VBD nonsynonymous_JJ mutations_NNS (_( see_VB below_IN )_) within_IN the_DT immunodominant_JJ region_NN harboring_VBG the_DT epitope_NN region_NN of_IN the_DT anti-gG-1_JJ MAb_NN ,_, including_VBG the_DT amino_NN acid_JJ F111->V_NP mutation_NN situated_VBN within_IN the_DT previously_RB mapped_VBN AFPL_NP epitope_NN of_IN the_DT MAb_NP ._SENT Where_WRB the_DT sex_NN of_IN the_DT patient_NN could_MD be_VB identified_VBN ,_, 54_CD strains_NNS were_VBD isolated_VBN from_IN females_NNS and_CC 22_CD were_VBD isolated_VBN from_IN male_JJ hosts_NNS ,_, but_CC the_DT reactivity_NN to_TO the_DT anti-gG-1_JJ MAb_NN was_VBD unrelated_JJ to_TO gender_VB ._SENT Of_IN the_DT two_CD patients_NNS who_WP each_DT had_VBD contributed_VBN two_CD strains_NNS ,_, one_PP harbored_VBD two_CD MAb-negative_JJ isolates_NNS while_IN the_DT other_JJ presented_VBD two_CD MAb-positive_JJ isolates_NNS ._SENT DNA_NP sequence_NN variations_NNS within_IN the_DT gG-1_JJ gene_NN ._SENT |_SYM To_TO more_RBR accurately_RB define_VB the_DT extent_NN of_IN genetic_JJ variability_NN among_IN the_DT MAb-positive_JJ and_CC MAb-negative_JJ isolates_NNS ,_, nucleotide_NN sequences_NNS were_VBD determined_VBN for_IN the_DT middle_JJ part_NN (_( 106_CD amino_NN acids_NNS )_) of_IN the_DT gG-1_JJ gene_NN including_VBG the_DT immunodominant_JJ region_NN and_CC the_DT type-specific_JJ epitope_NN region_NN for_IN the_DT anti-gG-1_JJ MAb_NN in_IN 105_CD of_IN the_DT 108_CD strains_NNS ._SENT The_DT results_NNS from_IN DNA_NP sequencing_NP showed_VBD that_IN all_DT 42_CD clinical_JJ isolates_NNS which_WDT were_VBD unreactive_JJ with_IN the_DT anti-gG-1_NP MAb_NP showed_VBD mutations_NNS similar_JJ to_TO those_DT that_IN we_PP observed_VBD in_IN a_DT previous_JJ study_NN for_IN strain_NN KOS_NP 321_CD ,_, which_WDT in_IN concordance_NN also_RB was_VBD unreactive_JJ to_TO the_DT anti-gG-1_JJ MAb_NP ._SENT The_DT results_NNS ,_, including_VBG those_DT from_IN phylogenetic_JJ comparison_NN ,_, showed_VBD that_IN two_CD main_JJ genetic_JJ variants_NNS of_IN the_DT gG-1_JJ gene_NN exist_VBP among_IN clinical_JJ and_CC laboratory_NN HSV-1_JJ strains_NNS in_IN the_DT Western_JJ world_NN (_( Fig._NN and_CC )_) ._SENT The_DT complete_JJ gG-1_JJ gene_NN was_VBD sequenced_VBN in_IN 25_CD consecutively_RB received_VBN isolates_NNS ,_, 21_CD strains_NNS of_IN which_WDT corresponding_JJ sera_NN were_VBD included_VBN in_IN the_DT serological_JJ assays_NNS ._SENT Sequence_NN alignment_NN of_IN these_DT and_CC previously_RB reported_VBD sequences_NNS suggested_VBD the_DT existence_NN of_IN two_CD genetic_JJ groups_NNS of_IN HSV-1_JJ strains_NNS ,_, one_PP represented_VBD by_IN KOS321_NP and_CC the_DT other_JJ by_IN Syn17+_NP ._SENT This_DT interpretation_NN was_VBD supported_VBN by_IN high_JJ bootstrap_NN values_NNS in_IN the_DT phylogenetic_JJ tree_NN based_VBN on_IN 115_CD sequences_NNS from_IN the_DT middle_JJ part_NN of_IN the_DT gG-1_JJ gene_NN ._SENT When_WRB five_CD putative_JJ recombinants_NNS were_VBD excluded_VBN ,_, the_DT bootstrap_NN value_NN was_VBD in_IN fact_NN 100_CD %_NN (_( not_RB shown_VBN )_) ._SENT The_DT nucleotide_NN difference_NN between_IN the_DT groups_NNS was_VBD 6.9_CD %_NN ,_, compared_VBN to_TO 1.0_CD and_CC 0.7_CD %_NN within_IN the_DT KOS321_NP and_CC Syn17+_NP groups_NNS ,_, respectively_RB ._SENT From_IN the_DT alignment_NN it_PP was_VBD apparent_JJ that_IN sequence_NN 34_CD (_( Fig._NN A_NP to_TO C_NP )_) was_VBD similar_JJ to_TO Syn17+_NP in_IN the_DT first_JJ part_NN of_IN the_DT sequence_NN (_( nt_NN 1_CD to_TO 100_CD )_) but_CC similar_JJ to_TO KOS321_NP in_IN the_DT second_JJ part_NN (_( nt_NN 101_CD to_TO 288_CD )_) ._SENT The_DT converse_NN was_VBD observed_VBN for_IN sequences_NNS 66_CD ,_, 67_CD ,_, 70_CD ,_, and_CC AF1177121_NP ._SENT Phylogenetic_JJ analysis_NN of_IN the_DT two_CD segments_NNS further_RBR supported_VBD that_IN these_DT sequences_NNS represent_VBP recombination_NN ,_, with_IN sequence_NN 34_CD showing_VBG a_DT Syn17+-KOS_NP pattern_NN and_CC 66_CD ,_, 67_CD ,_, 70_CD ,_, and_CC AF117121_NP showing_VBG a_DT KOS-Syn17+_NP pattern_NN ._SENT Detection_NN of_IN gG-1-negative_JJ virus_NN due_JJ to_TO a_DT single_JJ frameshift_NN mutation_NN ._SENT |_SYM During_IN the_DT sequencing_NP of_IN the_DT 42_CD HSV-1_JJ MAb-negative_JJ strains_NNS ,_, one_CD isolate_NN was_VBD detected_VBN that_IN harbored_VBN a_DT single_JJ frameshift_NN mutation_NN within_IN the_DT gG-1_JJ gene_NN with_IN a_DT subsequent_JJ lack_NN of_IN expression_NN of_IN the_DT type-specific_JJ gG-1_JJ epitope_NN ._SENT A_DT single_JJ insertion_NN of_IN a_DT cytosine_NN nucleotide_NN within_IN a_DT stretch_NN of_IN six_CD cytosines_NNS at_IN the_DT position_NN consisting_VBG of_IN nt_NN 211_CD to_TO 216_CD (_( amino_NN acids_NNS 71_CD to_TO 72_CD )_) was_VBD observed_VBN ,_, which_WDT resulted_VBD in_IN a_DT different_JJ reading_NN frame_NN and_CC a_DT premature_JJ stop_NN codon_NN at_IN position_NN 91_CD ._SENT Interestingly_RB ,_, the_DT serum_NN sample_NN drawn_VBN from_IN the_DT patient_NN harboring_VBG the_DT gG-1-negative_JJ isolate_NN showed_VBD the_DT presence_NN of_IN IgG_NP antibodies_NNS reactive_JJ with_IN the_DT gG-1_JJ antigen_NN at_IN a_DT titer_NN of_IN 1/800_CD ._SENT Furthermore_RB ,_, this_DT strain_NN was_VBD isolated_VBN from_IN the_DT genital_JJ region_NN ._SENT ELISA_NP assay_NN ._SENT |_SYM Fifty-three_NP serum_NN samples_NNS obtained_VBN from_IN patients_NNS from_IN which_WDT 55_CD HSV-1_NP strains_NNS were_VBD isolated_VBN were_VBD investigated_VBN in_IN this_DT study_NN ,_, and_CC the_DT OD_JJ values_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Of_IN these_DT serum_NN samples_NNS ,_, 36_CD sera_NN corresponded_VBN to_TO anti-gG-1_JJ MAb-reactive_JJ strains_NNS and_CC 17_CD sera_NN corresponded_VBN to_TO MAb-unreactive_JJ isolates_NNS ,_, respectively_RB ._SENT In_IN total_NN ,_, 10_CD sera_NN were_VBD negative_JJ in_IN the_DT type-specific_JJ gG-1_JJ ELISA_NP ,_, of_IN which_WDT 7_CD sera_NN were_VBD derived_VBN from_IN patients_NNS harboring_VBG MAb-reactive_JJ isolates_NNS and_CC 3_CD sera_NN were_VBD derived_VBN from_IN patients_NNS carrying_VBG MAb-unreactive_JJ strains_NNS ._SENT This_DT seronegativity_NN to_TO gG-1_JJ was_VBD considered_VBN to_TO be_VB due_JJ to_TO samples_NNS being_VBG collected_VBN during_IN early_JJ seroconversion_NN in_IN seven_CD cases_NNS ._SENT Of_IN these_DT ,_, two_CD sera_NN were_VBD HSV_NP IgM-positive_NP by_IN immunofluorescence_NN ._SENT The_DT immunofluorescence_NN test_NN is_VBZ based_VBN on_IN HSV-2_NP and_CC has_VBZ a_DT lower_JJR sensitivity_NN to_TO HSV-1_NP ,_, which_WDT could_MD explain_VB why_WRB the_DT test_NN was_VBD negative_JJ with_IN the_DT other_JJ sera_NN ._SENT Two_CD sera_NN were_VBD reactive_JJ in_IN a_DT low_JJ titer_NN in_IN the_DT type-common_NP HSV_NP test_NN ,_, which_WDT sometimes_RB shows_VBZ early_JJ reactivity_NN ,_, and_CC three_CD additional_JJ patients_NNS had_VBD primary_JJ genital_JJ HSV_NP infection_NN as_RB judged_VBN clinically_RB ._SENT Of_IN the_DT three_CD remaining_VBG patients_NNS with_IN gG-1-seronegative_JJ sera_NN ,_, one_PP carried_VBD a_DT MAb-reactive_JJ isolate_NN and_CC two_CD carried_VBD MAb-unreactive_JJ isolates_NNS ._SENT The_DT remaining_VBG 43_CD sera_NN were_VBD all_RB positive_JJ in_IN the_DT type-common_NN and_CC HSV-1_JJ type-specific_JJ gG-1_JJ ELISA_NP ._SENT Only_RB two_CD sera_NN were_VBD positive_JJ in_IN the_DT HSV-2_NP type-specific_JJ ELISA_NP ._SENT In_IN the_DT HSV_NP type-common_NN seroassay_NN ,_, mean_VBP OD_JJ values_NNS +-_NN standard_NN deviations_NNS were_VBD 0.68_CD +-_NN 0.47_CD in_IN sera_NN from_IN patients_NNS harboring_VBG anti-gG-1_JJ MAb-reactive_JJ isolates_NNS versus_IN 0.73_CD +-_NN 0.56_CD in_IN sera_NN from_IN hosts_NNS of_IN anti-gG-1_JJ MAb-unreactive_JJ isolates_NNS ._SENT In_IN the_DT HSV_NP type-specific_JJ gG-1_JJ seroassay_NN (_( gG-1_JJ )_) ,_, mean_JJ OD_JJ values_NNS +-_NN standard_NN deviations_NNS were_VBD 0.55_CD +-_NN 0.50_CD in_IN sera_NN from_IN patients_NNS harboring_VBG anti-gG-1_JJ MAb-reactive_JJ isolates_NNS versus_IN 0.43_CD +-_NN 0.38_CD in_IN sera_NN from_IN hosts_NNS of_IN anti-gG-1_JJ MAb-unreactive_JJ isolates_NNS ._SENT None_NN of_IN these_DT differences_NNS in_IN OD_JJ values_NNS between_IN the_DT two_CD groups_NNS were_VBD statistically_RB significant_JJ ._SENT FIG._NN 3_CD ._SENT |_SYM Aligned_NP deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT complete_JJ gG-1_JJ gene_NN for_IN 14_CD variants_NNS discovered_VBN in_IN 38_CD clinical_JJ and_CC reference_NN strains_NNS of_IN which_WDT 13_CD DNA_NP sequences_NNS were_VBD included_VBN from_IN a_DT previously_RB published_VBN report_NN (_( 26_CD )_) ._SENT Aligned_VBN deduced_VBD amino_NN acid_NN sequences_NNS of_IN the_DT complete_JJ gG-1_JJ gene_NN for_IN 14_CD variants_NNS discovered_VBN in_IN 38_CD clinical_JJ and_CC reference_NN strains_NNS of_IN which_WDT 13_CD DNA_NP sequences_NNS were_VBD included_VBN from_IN a_DT previously_RB published_VBN report_NN (_( 26_CD )_) ._SENT The_DT number_NN of_IN isolates_NNS corresponding_JJ to_TO each_DT genetic_JJ variant_NN is_VBZ given_VBN to_TO the_DT left_NN ._SENT The_DT proposed_VBN immunodominant_NN region_NN of_IN gG-1_NN is_VBZ shaded_JJ ,_, and_CC the_DT epitope_NN of_IN the_DT anti-gG-1_JJ MAb_NP reactivity_NN is_VBZ depicted_VBN in_IN boldface_JJ type_NN and_CC underlined_VBD ._SENT FIG._NN 4_CD ._SENT |_SYM Comparison_NN of_IN OD_JJ values_NNS in_IN ELISA_NP for_IN sera_NN drawn_VBN from_IN patients_NNS harboring_VBG MAb-negative_JJ or_CC MAb-positive_JJ isolates_NNS using_VBG a_DT type-common_NP HSV-antigen_NP and_CC an_DT HSV-1_JJ type-specific_JJ gG-1_JJ antigen_NN ._SENT Comparison_NN of_IN OD_JJ values_NNS in_IN ELISA_NP for_IN sera_NN drawn_VBN from_IN patients_NNS harboring_VBG MAb-negative_JJ or_CC MAb-positive_JJ isolates_NNS using_VBG a_DT type-common_NP HSV-antigen_NP and_CC an_DT HSV-1_JJ type-specific_JJ gG-1_JJ antigen_NN ._SENT Data_NNS are_VBP expressed_VBN as_IN the_DT mean_NN of_IN two_CD observations_NNS ._SENT Each_DT mean_JJ value_NN for_IN the_DT two_CD groups_NNS of_IN sera_NN (_( those_DT drawn_VBN from_IN patients_NNS with_IN anti-gG-1_JJ MAb+_NN or_CC anti-gG-1MAb-_NN strains_NNS )_) is_VBZ indicated_VBN by_IN a_DT horizontal_JJ bar_NN and_CC did_VBD not_RB differ_VB significantly_RB in_IN either_DT of_IN the_DT two_CD serological_JJ assays_NNS when_WRB analyzed_VBN with_IN Student_NP 's_POS t_NN test_NN ._SENT To_TO ensure_VB a_DT firm_NN base_NN for_IN the_DT use_NN of_IN gG-1_NN as_IN a_DT HSV-1_JJ type-specific_JJ antigen_NN ,_, we_PP here_RB determined_VBD the_DT genetic_JJ variability_NN of_IN the_DT gG-1_JJ gene_NN in_IN a_DT large_JJ number_NN of_IN clinical_JJ isolates_NNS ._SENT A_DT recently_RB characterized_VBN immunodominant_JJ region_NN of_IN the_DT protein_NN overlapping_VBG the_DT epitope_NN of_IN an_DT HSV-1_JJ type-specific_JJ anti-gG-1_JJ MAb_NN was_VBD therefore_RB of_IN special_JJ interest_NN ._SENT Previously_RB ,_, we_PP found_VBD several_JJ mutations_NNS within_IN this_DT region_NN when_WRB the_DT gG-1_JJ gene_NN was_VBD sequenced_VBN in_IN a_DT limited_JJ number_NN of_IN HSV-1_JJ isolates_NNS ,_, and_CC reactivity_NN to_TO an_DT anti-gG-1_JJ MAb_NN was_VBD early_RB reported_VBN by_IN Ackermann_NP et_FW al._FW to_TO differ_VB among_IN type_NN 1_CD strains_NNS ._SENT Here_RB ,_, we_PP utilized_VBD a_DT type-specific_JJ anti-gG-1-MAb_NN ,_, reactive_JJ with_IN amino_NN acids_NNS 110AFPL113_JJ ,_, for_IN screening_NN of_IN gG-1_JJ variants_NNS among_IN 108_CD clinical_JJ isolates_NNS ._SENT Altogether_RB ,_, 42_CD (_( 38_CD %_NN )_) of_IN the_DT clinical_JJ isolates_NNS showed_VBD no_DT reactivity_NN to_TO the_DT anti-gG-1_JJ MAb_NN ,_, and_CC by_IN DNA_NP sequencing_NP and_CC phylogenetic_JJ comparison_NN we_PP observed_VBD two_CD main_JJ genetic_JJ variants_NNS of_IN the_DT gG-1_JJ gene_NN that_WDT correlated_VBD to_TO the_DT absence_NN or_CC presence_NN of_IN MAb_NP reactivity_NN ._SENT Since_IN these_DT two_CD disparate_JJ genetic_JJ variant_JJ sequences_NNS of_IN gG-1_NN resulted_VBN in_IN up_IN to_TO 14_CD amino_NN acid_JJ alterations_NNS (_( see_VB below_IN )_) and_CC some_DT were_VBD localized_VBN to_TO the_DT immunodominant_JJ region_NN ,_, we_PP suspected_VBD that_IN the_DT two_CD variants_NNS might_MD also_RB differ_VB in_IN their_PP$ induction_NN of_IN IgG_NP antibody_NN response_NN to_TO gG-1_NN ._SENT If_IN this_DT was_VBD the_DT case_NN ,_, one_PP could_MD expect_VB different_JJ serological_JJ reactions_NNS between_IN the_DT two_CD groups_NNS in_IN the_DT HSV-1_JJ type-specific_JJ ELISA_NN based_VBN on_IN gG-1_JJ antigen_NN currently_RB in_IN use_NN ._SENT This_DT could_MD be_VB expressed_VBN as_IN a_DT low_JJ sensitivity_NN in_IN serotesting_NN of_IN patients_NNS harboring_VBG strains_NNS carrying_VBG one_CD of_IN the_DT other_JJ gG-1_JJ gene_NN variants_NNS if_IN the_DT antigen_NN used_VBN as_IN a_DT diagnostic_JJ tool_NN is_VBZ based_VBN on_IN the_DT sequence_NN of_IN the_DT other_JJ genetic_JJ variant_NN ._SENT A_DT low_JJ sensitivity_NN of_IN gG-1-based_JJ ELISA_NP kits_NNS in_IN clinical_JJ settings_NNS has_VBZ been_VBN described_VBN ._SENT To_TO investigate_VB this_DT ,_, we_PP compared_VBD the_DT serological_JJ reactions_NNS in_IN sera_NN from_IN patients_NNS infected_VBN with_IN isolates_NNS representing_VBG either_DT variant_NN of_IN gG-1_NN ._SENT However_RB ,_, no_DT differences_NNS in_IN IgG_NP reactivity_NN were_VBD found_VBN when_WRB sera_NN were_VBD tested_VBN by_IN the_DT gG-1_JJ ELISA_NP ._SENT In_IN addition_NN ,_, only_RB 3_CD of_IN the_DT 10_CD sera_NN that_WDT were_VBD found_VBN to_TO be_VB negative_JJ in_IN type-specific_JJ gG-1_JJ ELISA_NP were_VBD drawn_VBN from_IN patients_NNS harboring_VBG MAb-negative_JJ isolates_NNS ._SENT Instead_RB ,_, a_DT possible_JJ explanation_NN for_IN the_DT seronegativity_NN to_TO gG-1_NN could_MD be_VB that_IN these_DT sera_NN were_VBD collected_VBN early_RB during_IN infection_NN before_IN seroconversion_NN had_VBD occurred_VBN ._SENT In_IN fact_NN ,_, most_JJS of_IN the_DT gG-1-seronegative_JJ patients_NNS showed_VBD symptoms_NNS and/or_CC serological_JJ signs_NNS of_IN primary_JJ HSV-1_JJ infection_NN ._SENT Hence_RB ,_, we_PP suggest_VBP that_IN early_JJ infection_NN might_MD be_VB a_DT factor_NN contributing_VBG to_TO the_DT reported_VBN low_JJ sensitivity_NN to_TO gG-1_JJ antigen-based_JJ ELISA_NP ._SENT The_DT finding_NN that_IN only_RB two_CD of_IN the_DT sera_NN were_VBD reactive_JJ to_TO the_DT gG-2_JJ antigen_NN (_( lower_JJR than_IN expected_VBN from_IN seroepidemiological_JJ studies_NNS )_) could_MD be_VB explained_VBN by_IN the_DT large_JJ proportion_NN of_IN sera_NN derived_VBN from_IN what_WP was_VBD considered_VBN to_TO be_VB primary_JJ HSV-1_JJ infections_NNS ._SENT Furthermore_RB ,_, despite_IN the_DT fact_NN that_IN most_JJS of_IN the_DT corresponding_JJ viral_JJ isolates_NNS (_( 28_CD of_IN 53_CD )_) were_VBD derived_VBN from_IN the_DT genital_JJ tract_NN ,_, they_PP were_VBD typed_VBN as_IN HSV-1_NP ._SENT A_DT recent_JJ epidemiological_JJ report_NN from_IN our_PP$ geographical_JJ area_NN has_VBZ shown_VBN that_IN genital_JJ HSV-1_JJ infections_NNS are_VBP increasing_VBG ,_, thus_RB explaining_VBG why_WRB a_DT lower_JJR rate_NN of_IN HSV-2_NP seropositivity_NN might_MD be_VB encountered_VBN in_IN such_PDT a_DT selected_JJ patient_NN group_NN ._SENT The_DT clinical_JJ HSV-1_NP strains_NNS described_VBD herein_RB were_VBD isolated_VBN from_IN a_DT number_NN of_IN different_JJ anatomical_JJ sites_NNS ,_, such_JJ as_IN the_DT lip_NN ,_, ear_NN ,_, eye_NN ,_, other_JJ facial_JJ regions_NNS ,_, genital_JJ or_CC perianal_JJ regions_NNS ,_, and_CC the_DT nervous_JJ system_NN ._SENT Both_CC genetic_JJ variants_NNS were_VBD proportionally_RB isolated_VBN from_IN females_NNS and_CC males_NNS and_CC were_VBD present_JJ at_IN all_DT of_IN these_DT different_JJ body_NN regions_NNS with_IN the_DT possible_JJ exception_NN of_IN extralabial_JJ and_CC facial_JJ manifestations_NNS ,_, where_WRB none_NN of_IN five_CD isolates_NNS were_VBD MAb_NP negative_JJ ._SENT Thus_RB ,_, neither_CC of_IN the_DT two_CD variants_NNS could_MD be_VB associated_VBN with_IN anatomical_JJ site_NN or_CC gender_NN ._SENT The_DT dichotomy_NN of_IN the_DT gG-1_JJ DNA_NN sequences_NNS found_VBN among_IN clinical_JJ isolates_NNS was_VBD also_RB present_JJ when_WRB reference_NN strains_NNS originating_VBG from_IN United_NP States_NPS and_CC United_NP Kingdom_NP ,_, commonly_RB used_VBN for_IN experimental_JJ work_NN ,_, were_VBD sequenced_VBN and_CC included_VBN in_IN the_DT phylogenetic_JJ analysis_NN ._SENT The_DT anti-gG-1_JJ MAb-negative_JJ genetic_JJ variant_NN was_VBD represented_VBN by_IN KOS321_NP as_IN previously_RB described_VBN ,_, while_NN both_CC the_DT Syn17+_NP and_CC F_NP strains_NNS were_VBD found_VBN to_TO belong_VB to_TO the_DT MAb-positive_JJ branch_NN of_IN the_DT phylogenetic_JJ tree_NN ._SENT As_IN a_DT consequence_NN ,_, 14_CD of_IN 238_CD (_( similar6_NN %_NN )_) of_IN the_DT encoded_VBN amino_NN acid_NN residues_NNS within_IN gG-1_NN might_MD differ_VB between_IN reference_NN strains_NNS selected_VBN as_IN prototype_NN viruses_NNS for_IN diagnostic_JJ or_CC functional_JJ studies_NNS ._SENT Thus_RB ,_, by_IN using_VBG either_RB of_IN Syn_NP 17+_NP or_CC F_NP together_RB with_IN KOS321_NP for_IN studies_NNS of_IN expression_NN and_CC function_NN of_IN the_DT gG-1_JJ gene_NN ,_, the_DT genetic_JJ diversity_NN among_IN clinical_JJ isolates_NNS is_VBZ better_RBR represented_VBN in_IN the_DT experimental_JJ setting_NN ._SENT Documentation_NN of_IN genetic_JJ variability_NN among_IN clinical_JJ HSV_NP isolates_NNS is_VBZ limited_VBN and_CC was_VBD hitherto_RB performed_VBN mostly_RB by_IN RE_JJ analysis_NN ._SENT In_IN comparison_NN ,_, a_DT huge_JJ amount_NN of_IN data_NNS is_VBZ available_JJ at_IN the_DT nucleotide_NN level_NN for_IN several_JJ RNA_NP viruses_NNS such_JJ as_IN HIV_NP and_CC hepatitis_NP C_NP virus_NN ._SENT However_RB ,_, genetic_JJ variability_NN in_IN specific_JJ genes_NNS of_IN HSV-1_NP ,_, such_JJ as_IN the_DT gB-1_JJ gene_NN and_CC the_DT gD-1_JJ gene_NN ,_, after_IN PCR_NP amplification_NN performed_VBN on_IN clinical_JJ samples_NNS of_IN cerebrospinal_JJ fluid_NN has_VBZ been_VBN reported_VBN but_CC could_MD not_RB link_VB any_DT genetic_JJ variants_NNS to_TO the_DT clinical_JJ presentation_NN in_IN the_DT form_NN of_IN encephalitis_NN ._SENT As_RB regards_VBZ HSV-2_NP ,_, sequence_NN data_NNS ,_, derived_VBN from_IN clinical_JJ isolates_NNS ,_, on_IN genes_NNS encoding_VBG envelope_NN glycoproteins_NNS such_JJ as_IN gB_NN ,_, gC_NN ,_, gD_NN or_CC gG_NN have_VBP been_VBN presented_VBN ._SENT Taken_VBN together_RB ,_, these_DT studies_NNS showed_VBD the_DT occurrence_NN of_IN point_NN mutations_NNS ,_, which_WDT were_VBD mostly_RB silent_JJ and_CC coded_VBN for_IN insertion_NN or_CC deletion_NN of_IN one_CD or_CC a_DT few_JJ amino_NN acids_NNS ._SENT However_RB ,_, no_DT correlation_NN was_VBD found_VBN between_IN clinical_JJ conditions_NNS and_CC genetic_JJ variants_NNS ._SENT From_IN the_DT results_NNS of_IN the_DT sequencing_NP of_IN the_DT gG-1_JJ gene_NN ,_, we_PP observed_VBD additional_JJ mechanisms_NNS for_IN generating_VBG genetic_JJ variability_NN among_IN the_DT isolates_NNS :_: several_JJ possible_JJ recombinants_NNS of_IN the_DT two_CD genetic_JJ variants_NNS have_VBP been_VBN described_VBN here_RB as_RB well_RB as_IN a_DT frameshift_NN mutant_NN that_IN most_RBS likely_RB resulted_VBN in_IN a_DT gG-1-negative_JJ phenotype_NN ._SENT The_DT latter_JJ strain_NN was_VBD unreactive_JJ to_TO the_DT anti-gG-1_JJ MAb_NN but_CC showed_VBD only_RB a_DT single_JJ insertion_NN of_IN a_DT cytosine_NN nucleotide_NN within_IN a_DT stretch_NN of_IN six_CD cytosines_NNS at_IN the_DT N-terminal_JJ part_NN of_IN the_DT gG-1_JJ gene_NN ,_, resulting_VBG in_IN a_DT different_JJ reading_NN frame_NN and_CC a_DT premature_JJ stop_NN codon_NN ._SENT A_DT similar_JJ mechanism_NN explaining_VBG a_DT gG-2-negative_JJ phenotype_NN in_IN several_JJ HSV-2_NP isolates_NNS was_VBD also_RB recently_RB described_VBN from_IN our_PP$ laboratory_NN ._SENT Sequence_NN alignment_NN suggested_VBD that_IN five_CD sequences_NNS might_MD represent_VB recombination_NN of_IN two_CD segments_NNS of_IN gG-1_NN ._SENT Sequence_NN 34_CD appeared_VBD to_TO be_VB a_DT recombinant_JJ with_IN a_DT Syn17+-KOS321_JJ pattern_NN ._SENT Conversely_RB ,_, the_DT sequences_NNS 66_CD ,_, 67_CD ,_, 70_CD ,_, and_CC AF117121_NP showed_VBD a_DT KOS321-Syn17+_NP pattern_NN ,_, apparently_RB with_IN the_DT recombination_NN point_NN occurring_VBG at_IN the_DT same_JJ position_NN or_CC a_DT nearby_JJ position_NN ._SENT Phylogenetic_JJ analysis_NN carried_VBD out_RP for_IN each_DT segment_NN of_IN the_DT gG-1_JJ gene_NN further_RBR supported_VBD recombination_NN ._SENT In_IN all_DT ,_, 4_CD %_NN (_( 5_CD of_IN 115_CD )_) of_IN the_DT strains_NNS from_IN clinical_JJ samples_NNS showed_VBD signs_NNS of_IN recombination_NN ,_, indicating_VBG that_IN this_DT event_NN is_VBZ relatively_RB frequent_JJ and_CC also_RB that_IN these_DT recombinants_NNS are_VBP viable_JJ and_CC circulate_VB in_IN the_DT population_NN ._SENT Although_IN recombinants_NNS for_IN genes_NNS coding_VBG for_IN glycoproteins_NNS among_IN clinical_JJ HSV-1_NP isolates_NNS have_VBP not_RB ,_, to_TO our_PP$ knowledge_NN ,_, been_VBN described_VBN previously_RB ,_, homologous_JJ recombination_NN of_IN the_DT gB_NN gene_NN was_VBD reported_VBN after_IN coinfection_NN of_IN mice_NNS with_IN two_CD different_JJ HSV-1_JJ strains_NNS ._SENT Furthermore_RB ,_, a_DT study_NN of_IN CMV_NP DNA_NP in_IN clinical_JJ samples_NNS has_VBZ shown_VBN that_DT homologous_JJ recombination_NN of_IN the_DT gB_NN gene_NN has_VBZ occurred_VBN and_CC exists_VBZ in_IN several_JJ variants_NNS ._SENT In_IN conclusion_NN ,_, the_DT earlier-described_JJ variability_NN of_IN the_DT gG-1_JJ DNA_NN sequence_NN among_IN clinical_JJ isolates_NNS and_CC reference_NN strains_NNS was_VBD here_RB confirmed_VBN and_CC further_RBR defined_VBN as_IN a_DT dichotomy_NN in_IN a_DT large_JJ study_NN of_IN HSV-1_JJ clinical_JJ isolates_NNS ._SENT Ongoing_JJ studies_NNS are_VBP investigating_VBG whether_IN this_DT form_NN of_IN genetic_JJ diversity_NN is_VBZ also_RB present_JJ in_IN other_JJ HSV-1_JJ genes_NNS ._SENT Based_VBN on_IN the_DT hypothesis_NN that_IN HSV-1_JJ coevolves_NNS with_IN the_DT human_JJ host_NN ,_, a_DT DNA_NP sequence_NN comparison_NN with_IN strains_NNS isolated_VBN from_IN subjects_NNS in_IN distant_JJ parts_NNS of_IN the_DT world_NN would_MD be_VB of_IN interest_NN ._SENT Furthermore_RB ,_, recent_JJ studies_NNS relating_VBG gG-1_JJ to_TO apical_JJ entry_NN of_IN polarized_VBN cells_NNS raise_VBP the_DT question_NN of_IN whether_IN the_DT two_CD gG-1_JJ variants_NNS differ_VBP in_IN their_PP$ function_NN when_WRB contributing_VBG to_TO HSV-1_NP infectivity_NN ._SENT 